scholarly journals Back to the future with noninvasive biomarkers of liver fibrosis

Hepatology ◽  
2008 ◽  
Vol 49 (1) ◽  
pp. 9-11 ◽  
Author(s):  
Indra Neil Guha
Keyword(s):  
Liver Fibrosis ◽  
The Future ◽  
Noninvasive Biomarkers

Noninvasive Biomarkers for Liver Fibrosis

2020 ◽  
pp. 427-441
Author(s):  
Gamal Shiha ◽  
Nasser Mousa
Keyword(s):  
Liver Fibrosis ◽  
Noninvasive Biomarkers

Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis

2009 ◽  
Vol 16 (9) ◽  
pp. 612-620 ◽  
Author(s):  
E. Kovalenko ◽  
F. Tacke ◽  
O. A. Gressner ◽  
H. W. Zimmermann ◽  
B. Lahme ◽  
...  
Keyword(s):  
Growth Factor ◽  
Liver Fibrosis ◽  
Connective Tissue ◽  
Connective Tissue Growth Factor ◽  
Gene Polymorphisms ◽  
Tissue Growth ◽  
Its Gene ◽  
Noninvasive Biomarkers

scholarly journals Potential role of noninvasive biomarkers during liver fibrosis

2021 ◽  
Vol 13 (12) ◽  
pp. 1919-1935
Author(s):  
Navneet Kaur ◽  
Gitanjali Goyal ◽  
Ravinder Garg ◽  
Chaitanya Tapasvi ◽  
Sonia Chawla ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Potential Role ◽  
Noninvasive Biomarkers

scholarly journals The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients

2020 ◽  
Author(s):  
Enass A Abdel-hameed ◽  
Susan D Rouster ◽  
Shyam Kottilil ◽  
Kenneth E Sherman
Keyword(s):  
Liver Fibrosis ◽  
Hepatic Fibrosis ◽  
Liver Histology ◽  
Superior Performance ◽  
Metavir Score ◽  
Noninvasive Biomarker ◽  
Advanced Liver Fibrosis ◽  
Noninvasive Biomarkers ◽  
Liver Fibrosis Index ◽  
Hcv Coinfection

Abstract Background Accurate noninvasive biomarkers of fibrotic progression are important for hepatitis C virus (HCV) management, but commonly used modalities may have decreased efficacy in human immunodeficiency virus (HIV)/HCV-coinfected persons. The enhanced liver fibrosis (ELF) index is a highly sensitive noninvasive marker of hepatic fibrosis that has had limited assessment in the HIV/HCV population. We compared ELF index performance to FIB4 and aspartate to platelet ratio index (APRI) at different stages of liver fibrosis as determined by liver histology, and validated the efficacy of the three noninvasive biomarkers in HIV/HCV-coinfected versus HCV-monoinfected. Methods The ELF index was determined in 147 HIV/HCV-coinfected and 98 HCV-monoinfected persons using commercial ELISA assays for the component elements of the index. Area under the receiver-operator curve was used to validate ELF and to compare its performance to liver histology as well as to other noninvasive biomarkers of liver fibrosis, FIB4, and APRI. Results The ELF index increased with histological stage of liver fibrosis and exhibited a linear relationship with Metavir score in all subjects. ELF performance was comparable between HIV/HCV and HCV with advanced liver fibrosis/cirrhosis. In the HIV/HCV cohort ELF cutoffs of 8.45 and 9.23 predicted mild and moderate fibrosis with 85% sensitivity, whereas the ELF cutoff of 9.8 had the highest specificity for advanced fibrosis and the cutoff of 10.4 was 99% specific for cirrhosis. ELF performance was superior to FIB4 and APRI in all subjects regardless of HIV status. Conclusions ELF index demonstrated excellent characteristics toward accurate prediction of liver fibrosis and cirrhosis with superior performance to APRI and FIB4 in HIV/HCV coinfection. Applying this noninvasive biomarker index for diagnosis of liver fibrosis and progression in HIV/HCV is warranted.

scholarly journals Noninvasive methods for the assessment of liver fibrosis: A window open on the future?

Hepatology ◽  
2011 ◽  
Vol 54 (4) ◽  
pp. 1476-1477 ◽  
Author(s):  
Massimo Pinzani
Keyword(s):  
Liver Fibrosis ◽  
Noninvasive Methods ◽  
The Future

scholarly journals In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?

2016 ◽  
Vol 3 ◽  
pp. 53-53 ◽  
Author(s):  
Erica Novo ◽  
Stefania Cannito ◽  
Maurizio Parola
Keyword(s):  
Liver Fibrosis ◽  
The Future

scholarly journals THE DAAS TREATMENT OF CHRONIC HCV INFECTION AND THE LIVER FIBROSIS EVOLUTION DURING TREATMENT: OUR EXPERIENCE

2016 ◽  
Vol 19 (3) ◽  
pp. 50-54
Author(s):  
Andreea Rădășan ◽  
◽  
Mihai Voiculescu ◽  
Laura Elena Iliescu ◽  
◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Acute Infection ◽  
Hepatitis C Infection ◽  
Time Period ◽  
The Future ◽  
Chronic Hcv ◽  
Inflammatory Syndrome

Introduction. Hepatitis C is a liver inflammation caused by hepatitis C virus. HCV is about 10 times as infectious as HIV. The acute infection rarely causes symptoms and can clear up spontaneously in the first six months in about 20% of those affected. In most cases, however, the infection becomes chronic (up to 80%)6. Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide7. In the past decades, the standard treatment for hepatitis C viral infection was PEG-IFN and ribavirin (RBV). The future for the treatment of chronic hepatitis C infection is represented by DAAs and for Romania, the future is called Exviera+Viekirax. Objective of the study: The main purpose of the survaillance was to determine how these HCV chronic infection patients with F4 liver fibrosis tolerate the new DAAs treatment and how the liver fibrosis will decrease or increase. Matherial and methods: The study enrolled 33 patients from Internal Medicine Center, Fundeni Clinical Institute, during the time period 02.2016 – 08.2016. We evaluated the inflammatory syndrome, the cholestatic syndrome and the evolution of liver fibrosis. Results: We have noticed a significant decrease of inflammatory syndrome, the bilirubin level decreased also, but the stage of liver fibrosis remained the same, at the end of treatment with Eviera+Viekirax. Conclusions: We had a small experience so far, with Exviera+Viekirax regimen. The patients tolerated very well the therapy and the virological response was 100% for all subjects.

scholarly journals Handgrip Strength and Vitamin D as Predictors of Liver Fibrosis and Malnutrition in Chronic Hepatitis C Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Sami A. Gabr ◽  
Ahmad H. Alghadir
Keyword(s):  
Vitamin D ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Muscle Mass ◽  
Handgrip Strength ◽  
Control Subjects ◽  
Noninvasive Biomarkers ◽  
And Control

Background. In patients with chronic hepatitis C (CHC), a negative impact of associated malnutrition on both morbidity and mortality was reported. We aimed to elucidate the efficacy of serum liver fibrosis markers (fibronectin (FN), hydroxyproline (Hyp), and hyaluronic acid (HA)) and their respective indices (HA index, Hyp index, and FN index) and vitamin D status in predicting malnutrition associated with liver fibrosis in CHC patients and to investigate their association with the value of current clinical malnutrition assessment tools subjective global assessment (SGA), handgrip strength (HGS), and muscle mass scores (SGA, BMI, MAMC, and HGS). Materials and Methods. A cross-sectional study was conducted on 80 patients aged 40-60 years with proven viremia, HCV antibodies, HCV-RNA positivity, genotype determinations, and established chronic hepatitis C virus for more than 6 years and 80 control subjects. SGA, HGS, and muscle mass score (MAMC) were estimated in both patients and control subjects. Based on SGA scores, CHC patients were classified into three groups: well nourished ( n = 12 ; SGA-A); mild or moderately malnourished ( n = 25 ; SGA-B); and severely malnourished ( n = 43 ; SGA-C). Liver fibrosis markers, inflammatory indicator α-Fetoprotein (AFP), tumor necrosis factor-alpha (TNF-α), 25-hydroxyvitamin D, and PTH were estimated using immunoassay techniques. Results. CHC patients with moderate and severe malnutrition SGA scores showed a significant decline in the levels of vitamin D, increased PTH, and lower values of HGS and muscle mass indices compared to well-nourished patients and control subjects. In addition, malnutrition, vitamin D deficiency, and lower values of HGS, MAC, TSF, and MAMC showed significant correlation with liver severity among CHC patients. Liver fibrosis markers Hyp, HA, FN, APRI, HypI, HAI, and FNI as noninvasive biomarkers showed significant correlation with both severity of liver diseases and associated malnutrition, especially in cirrhotic HCV patients (F4) compared to those with significant fibrosis (F2–F3). Conclusion. The results showed that deficiency in vitamin D levels, HGS, SGA, and muscle mass scores (MAC, MAMC, or TSF) could be used as markers of liver pathogenicity in patients with CHC. In addition, the study concluded that noninvasive biomarkers Hyp, HA, FN, APRI, HypI, HAI, and FNI separately or in association with vitamin D status, HGS, SGA, and muscle mass scores (MAC, MAMC, or TSF) were significantly associated with an incidence of malnutrition between ~70.5% and 89.6% of CHC patients with significant fibrosis and cirrhosis.

473 Diagnostic performance of noninvasive biomarkers of liver fibrosis and cirrhosis in chronic hepatitis B

2006 ◽  
Vol 44 ◽  
pp. S176
Author(s):  
G. Sebastiani ◽  
A. Vario ◽  
E. Noventa ◽  
M. Guido ◽  
R. Pistis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Diagnostic Performance ◽  
Noninvasive Biomarkers
Sign in / Sign up

Export Citation Format

Share Document